Mobilized peripheral blood stem cells (PBSC) are an attractive vehicle for cancer gene therapy. However these stem cells may have a reduced proliferative capacity due to previous cytotoxic chemotherapy treatment of the patient. In addition, primitive hematopoietic stem cells (HSC) from mobilized peripheral blood are almost exclusively quiescent, which makes it hard to induce proliferation in vitro and thus to improve stable transduction of introduced genes into a sufficiently large number of primitive stem cells. In this study CD34-selected mobilized PBSC from lymphoma and myeloma patients were used as target cells for retroviral-mediated gene transfer using a clinically relevant cell-and serum-free supernatant transduction protocol. We have investigated various parameters that may contribute to an improvement of the poor transduction efficiency of the primitive HSC, including prestimulation time, the use of the carboxy-terminal fibronectin fragment CH-296, as well as stromal cell line conditioned media. Retroviral supernatant transduction in combination with CH-296 increased significantly the gene transfer efficiency as compared to supernatant alone and made the use of polycations redundant. Gene transfer of primitive HSC (cobblestone area forming cell (CAFC) week 6) was specifically improved when this procedure was preceded by a 5-day pre-culture period as compared to a 2-day transduction procedure. However, irrespective of the numerical recovery, the CAFC week 6 after retroviral transduction produced less long-term culture colony-forming cells, suggesting a loss of individual stem cell quality. The addition of stroma-conditioned media during the pre-culture period did not affect the individual CAFC quality or transduction efficiency, but increased greatly the recovery of the total number of transduced and untransduced HSC leading to larger grafts containing higher numbers of transduced stem cells.
Introduction
Mobilized peripheral blood stem cells (PBSC) are widely used for autologous transplantation in cancer patients and have been proposed as a vehicle for cancer gene therapy using retroviral vectors. 1 However, there is only a limited number of clinically relevant gene transfer studies reporting on the transduction efficiency and recovery of primitive hematopoietic stem cells (HSC) from mobilized peripheral blood of cancer patients. 2, 3 One of the gene therapy strategies is to introduce drug resistance genes to prevent myelosuppression following chemotherapy. [3] [4] [5] The most desirable approach in human gene therapy trials is a cell-free virus-containing supernatant transduction protocol, but clinical trials using this supernatant approach have demonstrated low levels of gene delivery to repopulating HSC. 2, [6] [7] [8] [9] Although mobilized PBSC are clinically the most relevant target cells for cancer gene therapy in adult patients, these cells are likely to be resistant to stable integration of transduced genes. It has been shown that primitive HSC from mobilized peripheral blood are quiescent [10] [11] [12] [13] and refractory to cell cycle activation. 12, 13 while stable retroviral gene transfer occurs only in cells which are actively replicating at the time of virus infection. 14, 15 Recently, it is has been shown that coating of the culture surface with carboxy-terminal fibronectin fragments (FN 30/35 or CH-296) 16, 17 significantly improves retroviral supernatant transduction of progenitors and primitive stem cells from normal bone marrow and umbilical cord blood cells by colocalization of virus particles and HSC. [18] [19] [20] [21] However, to our knowledge it has not yet been reported whether mobilized CD34-positive (CD34 + ) PBSC from cancer patients similarly adhere to CH-296 as normal bone marrow and umbilical cord blood cells, and whether this adherence improves retroviral transduction and stem cell recovery.
In this study, we investigated the optimization of retroviral neomycin phosphotransferase (neo) gene supernatant transduction of primitive HSC in mobilized CD34-selected peripheral blood autologous transplants of multiple myeloma and non-Hodgkin lymphoma patients using CH-296 coating. Because previous studies have shown that primitive CD34 + CD38-negative HSC of the majority of mobilized peripheral blood samples which have been tested are refractory to cell cycle activation during a 2 to 3 days of cytokine stimulation, 12, 13 we also included a pre-culture period of 5 days. Using this pre-culture protocol the effect of the murine FBMD-1 and human L88/5 stroma-conditioned media (SCM) on the transduction efficiency and recovery of HSC was investigated, because we have shown previously that the use of SCM considerably improves the recovery of HSC from serum-free liquid cultures stimulated with interleukin-3 (IL-3), stem cell factor (SCF) and IL-6. 22, 23 The human CAFC assay was used to measure the frequency of different HSC subsets. CAFC week 2 to 4 are tentative indicators of the frequency of progenitor cells and transiently repopulating HSC, while the CAFC week 6 frequency is assumed to be an indicator of more primitive, long-term repopulating stem cells. 24, 25 By determining the absolute number of CAFC before and after transduction the recovery of various HSC subsets could be assessed. In order to allow parallel CAFC assays under G418 selection, providing the number and percentage of functional neo gene expressing stem cells, we transduced the supportive stromal cell line FBMD-1 with the neo gene which transfers G418 resistance. In addition, the colony-forming cell (CFC) production in flask long-term cultures (LTC-CFC) was performed as an estimate of total graft quality. 24, 25 These assays allowed a detailed quantitative and qualitative analysis of different HSC subsets.
Materials and methods

Mobilized peripheral blood
Cells from leukapheresis products of five non-Hodgkin lymphoma and five multiple myeloma patients were used in this study. Before leukapheresis, the HSC were mobilized to the blood after several courses of chemotherapy using granulocyte colony-stimulating factor (Filgrastim, recombinant-methionyl human G-CSF; Roche, Mijdrecht, The Netherlands) as described before. 25 After cell collection, excess of erythrocytes was removed using buffy coat centrifugation. Fresh or frozen and thawed leukaphereses were subjected to a density gradient (1.077 g/ml, Lymphoprep; Nycomed, Olso, Norway) following CD34 selection (MACS CD34 isolation kit; Miltenyi Biotec, Bergisch Gladbach, Germany) to enrich for HSC. After selection the percentage CD34
+ cells was determined as described before (range 78-96% CD34 + cells). 25 
Cytokines
The following purified recombinant cytokines were kindly provided: human granulocyte-macrophage-CSF (GM-CSF), human IL-6 and murine SCF from Genetics Institute (Cambridge, MA, USA), human G-CSF and human SCF from Amgen (Thousand Oaks, CA, USA) and human IL-3 from Gist Brocades (Delft, The Netherlands).
CH-296 fibronectin fragement adhesion experiments
Adhesion experiments were performed in 35 mm bacterial dishes (Greiner, Alphen a/d Rijn, The Netherlands) coated with CH-296 (8 g/cm 2 ; Takara Shuzo, Otsu, Shiga, Japan) dissolved in phosphate-buffered saline (PBS; Gibco, Breda, The Netherlands) for 2 h at room temperature. Subsequently the dishes were blocked with 2% bovine serum albumin (BSA, A9418; Sigma, St Louis, MO, USA) in PBS for 30 min and washed with Hank's balanced salt solution (Gibco). Eighty thousand CD34
+ PBSC in serum-free medium were plated in CH-296-coated dishes. The cells were incubated for 30 to 120 min at 37°C and 10% CO 2 . After the incubation the nonadherent (NA) cells were removed from the dishes and after two rinses with Iscove's modified Dulbecco's medium with Glutamax-1 (IMDM; Gibco) replaced by 1 ml of 0.1% trypsin-EDTA (Gibco) for 5 min. The digestion was stopped by adding 1 ml of ice-cold fetal calf serum (FCS; Summit, Fort Collins, CO, USA). Subsequently, the adherent cells were collected from the dishes after scraping with a cell scraper (Greiner) and rinsing with IMDM. The adherent and NA cell fractions were assayed separately for the presence of CFC and CAFC weektypes.
Serum-free stroma-conditioned media Confluent layers were grown of the stromal cell lines FBMD-1 and L88/5. 24, 26, 27 The cells were cultured in IMDM supplemented with 10% FCS, penicillin (100 U/ml; Gibco), streptomycin (100 g/ml; Gibco) and 10 −4 M ␤-mercapto-ethanol (Merck, Darmstadt, Germany). The FBMD-1 cells were maintained at 33°C and 10% CO 2 and the L88/5 cells at 37°C and 10% CO 2 . When the layers were confluent, the medium was removed and rinsed twice with IMDM. Serum-free medium was added to the confluent stromal layers and conditioned for 7 days. This serum-free medium was prepared from IMDM containing 1% BSA, penicillin (100 U/ml), streptomycin (100 g/ml), 10 −4 M ␤-mercapto-ethanol, bovine insulin (10 g/ml; Gibco), 15 M cholesterol (Sigma), 15 M linolic acid (Merck), iron-satured human transferrin (0.62 g/l; Intergen, Purchase, NY, USA), cytidine (1 g/ml; Sigma), adenosine (1 g/ml; Sigma), uridine (1 g/ml; Sigma), guanosine (1 g/ml; Sigma), thymidine (1 g/ml; Sigma), 2Ј-deoxycytidine (1 g/ml; Sigma), 2Ј-deoxyadenosine (1 g/ml; Sigma), 2Ј-deoxyguanosine (1 g/ml; Sigma). The SCM were harvested and the NA cells were removed by centrifugation. Subsequently, the SCM were concentrated 20 times using a 30K ultrafiltration (Amicon, Beverly, MA, USA) and stored at −80°C until use. Control experiments indicated that this concentrated SCM contained the same activity as the unconcentrated SCM which has been used in previous experiments (DA Breems, unpublished observations). 22, 23 Serum-free neo virus supernatant After selection in medium (IMDM with 10% FCS, penicillin (100 U/ml), streptomycin (100 g/ml) and 10 −4 M ␤-mercaptoethanol) containing G418 (0.4 mg/ml, active substance; Gibco), 30 M hypoxanthine (Sigma), 1 M amethopterin (Sigma) and 20 M thymidine (Sigma), the retroviral-packaging cell line PA317/MSCVv2.1neo containing a MSCV vector in which the neo gene is placed under the transcriptional control of an internal phosphoglycerate kinase promotor 28 was grown to confluence in medium without selection drugs. When the layers were confluent, the medium was removed and rinsed twice with IMDM. Serum-free medium was added to the confluent stromal layers and conditioned for 18 h. The neo virus-containing supernatant was harvested and all cells were removed by 0.45 m filtration (Schleicher and Schuell, Dassel, Germany). The neo virus was stored at −80°C until use and after thawing the titer was 10 6 CFU/ml using a titration on 3T3 cells.
Serum-free liquid (pre-)culture
Serum-free liquid cultures were performed in 35 mm bacterial dishes without any coating to prevent strong adherence of the hematopoietic cells to the plastic surface. Eighty thousand CD34 + PBSC in 2 ml serum-free medium supplemented with IL-3 (25 ng/ml), human SCF (100 ng/ml), IL-6 (100 ng/ml) and anti-human-transforming growth factor-␤1 (␣TGF␤1; 1.0 g/ml; R&D Systems, Abingdon, UK) with or without 20 times concentrated SCM (50 l/ml) were cultured at 37°C and 10% CO 2 . SCM was only used during the 5-to 7-day serum-free liquid (pre-)cultures and not during the 2-day retroviral transduction procedure. At the end of the culture period, the cells were collected from the dishes after scraping with a cell scraper and rinsing with IMDM.
Retroviral transduction culture
Retroviral transduction was performed in 35-mm bacterial dishes coated with CH-296 dissolved in PBS for 2 h at room temperature. Subsequently the dishes were blocked with 2% BSA in PBS for 30 min and washed with Hank's balanced salt solution. Eighty thousand CD34 + PBSC were directly or after a serum-free liquid pre-culture period plated in CH-296-coated dishes ( Figure 1 ). During the transduction procedure the CD34 + PBSC were cultured with neo virus supernatant supplemented with IL-3, SCF, IL-6 and ␣TGF␤1 (3/S/6/␣T) for 48 h at 37°C and 10% CO 2 unless indicated otherwise. After the first 24 h, the neo virus supernatant was replaced by fresh supernatant, cytokines and ␣TGF␤1. The NA cells were returned to the transduction culture after centrifugation. At the end of the transduction period, the NA cells were collected from the dishes and after two rinses with IMDM replaced by 1 ml of 0.1% trypsin-EDTA for 5 min. The digestion was stopped by adding 1 ml of ice-cold FCS and the dishes were scraped with a cell scraper to include still adherent cells.
Colony forming cell assay
Quantification of the number of colony-forming units granulocyte/macrophage (CFU-GM) and burst-forming units erythroid (BFU-E) was performed using a semisolid CFC assay containing erythropoietin (Boehringer, Mannheim, Germany), G-CSF, GM-CSF, IL-3 and murine SCF as described before. 25 CFU-GM and BFU-E were counted on day 14 of culture in the same dish. To select for neo gene expressing CFC G418 (0.5 and 1.0 mg/ml, active substance) was added to the cultures.
Transduction of FBMD-1 cell line with a neo gene
In order to be able to perform CAFC assays under selective conditions, we prepared a G418-resistant FBMD-1 cell line (FBMD-neo). FBMD-1 cells growing in log-phase were cultured four 18 h in a serum-free neo virus supernatant with 10% FCS and polybrene (7.5 mg/ml; Sigma) at 37°C and 10% CO 2 . After this bulk transduction, the cells were selected and expanded for 10 days in IMDM supplemented with 10% FCS, 5% horse serum (Integro, Zaandam, The Netherlands), 10 −5 M hydrocortisone 21-hemisuccinate (Sigma), penicillin (100 U/ml), streptomycin (100 g/ml), 10 −4 M ␤-mercapto-ethanol and G418 (0.5 mg/ml, active substance) at 33°C and 10% CO 2 . Multiple ampules of the FBMD-neo cell line were stored in liquid nitrogen until use. Although control experiments showed that this FBMD-neo cell line had the same stem cell supportive capacity as the FBMD-1 cell line (PB Van Hennik and DA Breems, unpublished observations), in individual experiments either the FBMD-1 or the FBMD-neo cell line was used.
Long-term cultures in flasks
Confluent stromal layers of FBMD-1 or FBMD-neo cells in 25-cm 2 flasks (Costar, Cambridge, MA, USA) were overlaid with 30 000 CD34
+ PBSC or the output of 30 000 transduced CD34 + PBSC. The cells were cultured in IMDM supplemented with 10% FCS, 5% horse serum, 10 −5 M hydrocortisone 21-hemisuccinate, penicillin (100 U/ml), streptomycin (100 g/ml) and 10 −4 M ␤-mercapto-ethanol. IL-3 (10 ng/ml) and G-CSF (20 ng/ml) were added weekly to the cultures. Flaskcultures were set up in duplicate and maintained at 33 †C and 10% CO 2 for 6 weeks with weekly half-medium changes and therefore removal of half of the NA cells. The NA-CFC output of individual flask cultures was determined on week 2, 4 and 6 and was not corrected for the weekly demidepopulations.
At the end of 6 weeks the number of CFC in the adherent layer was also determined. To this purpose, the NA cells were collected from the flasks and after two rinses with IMDM replaced by 3 ml of 0.1% trypsin-EDTA for 5 min. The digestion was stopped by adding 1 ml of ice-cold FCS and the flasks were scraped with a cell scraper to include still adherent cells. The NA and adherent cell fractions were pooled and a single cell suspension was made by sieving the cell suspension through a 100 m nylon filter. The cell suspension was taken up in IMDM and several concentrations of the cell suspension were plated in a semisolid CFC cell assay.
Cobblestone area forming cell assay Limiting dilution CAFC assays were performed on confluent stromal layers of FBMD-1 or FBMD-neo cells in flat-bottom 96-well plates (Falcon, Franklin Lakes, NJ, USA). The cultures were maintained under the same conditions as the LTC in flasks. CD34
+ PBSC were overlaid in a limiting dilution setup. Twelve dilutions two-fold apart were used for each sample with 15 replicate wells per dilution. The percentage of wells with at least one phase-dark hematopoietic clone of at least five cells (ie cobblestone area) beneath the stromal layer was determined at week 2, 4 and 6 and CAFC frequencies were calculated using Poisson statistics. To select for neo gene expressing CAFC parallel G418 (0.5 mg/ml, active substance) containing CAFC assays were performed. In CAFC assays without G418 the highest concentration of cells was 1000 CD34
+ PBSC or the output of 1000 transduced CD34 + PBSC per well, while this concentration was two-fold higher in the CAFC assays with G418.
Statistical analysis
Data were analyzed using GraphPad Instat (GraphPad Software, San Diego, CA, USA). The means of two populations were compared using a paired Student's t-test.
Results
Adherence of CD34
+ mobilized PBSC to CH-296
Before studying the effect of CH-296 coating on retroviral transduction in CD34 + PBSC, we first investigated adherence of various stem cell subsets to the fibronectin fragment, and checked whether CH-296 adherence did not adversely affect or inhibit progenitor cell recovery after liquid culture. Adherence of CD34 + PBSC to CH-296 was studied by incubation in bacterial dishes coated with CH-296 in serum-free medium at 37°C for 30 to 120 min. After the incubation the adherent and NA fraction were assayed separately for the presence of CFC and CAFC week-types. More than 90% of the CFC and CAFC subsets adhered to CH-296 within 30 min of incubation (Table 1) . A control experiment showed that only 4 to 10% of the different stem cell subsets adhered to tissue culture plastic.
CH-296 adherence does not influence the recovery of CFC in short-term cultures
To test the effect of CH-296 adherence on the recovery of CFC after 2-and 7-day cultures, CD34
+ PBSC were plated in BSA- coated or CH-296-coated bacterial dishes with serum-free medium containing 3/S/6/␣T with or without FBMD-1 or L88/5 SCM. After 2 or 7 days of culture no effect of CH-296-mediated adherence on the recovery CFC was observed ( Figure 2 ). The recently reported positive effect of FBMD-1 and L88/5 SCM on the expansion of CFC after 7 days of culture was also not affected by the adherence to CH-296. 22, 23 CH-296 improves retroviral gene transfer efficiency of CFC A 2-day transduction procedure in which serum-free neo virus supernatant containing 3/S/6/␣T was added at day 0 and day 1 was performed on BSA-coated or CH-296-coated bacterial dishes. At day 2 the percentage G418-resistant (1.0 mg/ml, active substance) CFC was determined. Untransduced control cultures contained Ͼ0.1% G418-resistant CFC (data not shown). From transduction cultures on BSA-coated bacterial dishes 1.2% G418-resistant CFC were recovered ( Figure 3 ). This percentage was significantly (P Ͻ 0.0001) improved to
Figure 1
Four transduction protocols. 2T: 2-day transduction procedure; 2T5C: 2-day transduction followed by 5-day liquid culture; 2T3C2T: 2-day transduction followed by 3-day liquid culture and a second 2-day transduction; 5C2T: 5-day liquid culture followed by 2-day transduction. MSCVneo vector supernatant was added once a day (↑).
9.5% using CH-296-coated dishes. Interestingly, the addition of polybrene (7.5 mg/ml) or protamine sulphate (7.5 mg/ml; Novo Nordisk, Zoeterwoude, The Netherlands) could not further improve the transduction efficiency.
Titration of G418-concentration
In the experiments presented in Figure 3 , the stringent selection with 1.0 mg/ml G418 (active substance) may have caused an underestimation of the transduction efficiency. Therefore, titration experiments were performed to study this problem. Figure 4 shows that transduced CD34 + PBSC form 18.0% and 4.1% G418-resistant CFC in 0.5 and 1.0 mg/ml G418, respectively. In 1.0 mg/ml G418 no background CFC were formed by untransduced CD34 + PBSC (Ͻ 0.1%), while in 0.5 mg/ml G418 1.9% background CFC were found. As a result, by reducing the G418 concentration from 1.0 to 0.5 mg/ml the sensitivity of the G418 selection was increased with a small loss of specificity. Therefore, a lower G418 concentration (0.5 mg/ml) was used in the experiments presented in Figures 5, 6 and 7 and the background G418 resistance is presented in these Figures. From the experiments shown in Figures 5 and 6 it also became apparent that it was very difficult to find the ideal G418 concentration to select for G418-resistant CAFC week-types. For the CAFC week 2 0.5 mg/ml G418 was perhaps too low (background: 8.1%), while for the CAFC week 6 this concentration was probably too stringent (background: Ͻ0.1%).
Pre-culture specifically improves retroviral gene transfer into primitive HSC Because primitive HSC from mobilized peripheral blood are mostly noncycling cells, the effect of prolonged culture proto-
Figure 2
The effect of CH-296 adherence on the recovery of colony forming cells (CFC) in short-term cultures. The recovery of CFC is shown after 2-and 7-day cultures of CD34 + PBSC plated in BSAcoated () or CH-296-coated () bacterial dishes with serum-free medium containing IL-3, SCF, IL-6 and ␣TGF␤1 with or without FBMD-1 or L88/5 stroma-conditioned medium (SCM) as compared to input values at day 0 (dashed line).
Figure 3
The effect of CH-296 adherence on the retroviral gene transfer efficiency of colony forming cells (CFC). The percentage G418-resistant (1.0 mg/ml, active substance) CFC is shown after a 2-day transduction procedure of CD34 + PBSC in serum-free medium containing IL-3, SCF, IL-6 and ␣TGF␤1 on BSA-coated () or CH-296-coated () bacterial dishes and in the presence or absence of polybrene or protamine sulphate. Comparison between BSA coating and CH-296 coating: *, P Ͻ 0.02; **, P Ͻ 0.0001.
Figure 4
Titration of G418-concentration using colony-forming cell (CFC) assays. The percentage G418-resistant CFC is shown of untransduced () and transduced CD34 + PBSC () at different concentrations of G418. Data represent the means of five independent experiments.
Figure 5
The effect of different transduction protocols on retroviral neo gene transfer in and recovery of different stem cell subsets. cols on retroviral neo gene transfer in different stem cell subsets was studied. For this purpose four different serum-free transduction protocols containing 3/S/6/␣T were developed (Figure 1 ). The first protocol (2T) was a 2-day transduction procedure in which serum-free neo virus supernatant containing 3/S/6/␣T was added at day 0 and day 1. This protocol was compared with a second in which a 2-day transduction was followed by a 5-day liquid culture period (2T5C), a third protocol in which a 2-day transduction was preceded by 5-day liquid culture period (5C2T) and a last protocol in which a 2-day transduction was followed by a 3-day culture period and a second 2-day transduction (2T3C2T). All four protocols resulted in a comparable transduction percentage of progenitor cells (10.4 to 17.1% G418-resistant CFC and CAFC week 2) (Figure 5a ). In contrast, the highest gene transfer efficiency of primitive CAFC week 6 was obtained with the protocol in which a 2-day transduction was performed after 5-day preculture (5C2T: 8.7%; P Ͻ 0.05 as compared to 2T and 2T5C) and the protocol of 2-day transduction, 3-day culture and 2-day transduction (2T3C2T: 5.4%; P Ͻ 0.05 as compared to 2T and 2T5C), respectively, while the two other protocols with only retroviral supernatant addition in the first 2 days gave only 0.7% (2T) and 1.1% (2T5C) transduction.
We also studied the effect of these protocols on total recovery of stem cell subsets after transduction (Figure 5b) . The CFC showed a modest expansion (185 to 261% as compared to day 0) in the transduction protocols with a total length of 7
Figure 6
The effect of stroma-conditioned media (SCM) on retroviral neo gene transfer in and recovery of different stem cell subsets. (a) The percentage G418-resistant (0.5 mg/ml, active substance) colony-forming cells (CFC) and cobblestone area forming cell (CAFC) week-types, (b) the percentage recovery of CFC and CAFC week-types as compared to input values at day 0 (dashed line) and (c) the total recovery of G418-resistant CFC and CAFC week-types is shown using the 5C2T transduction protocol (see Figure 4 ) in serum-free medium containing IL-3, SCF, IL-6 and ␣TGF␤1 with or without FBMD-1 or L88/5 SCM. Percentage and number G418-resistant CFC and CAFC subsets of untreated cells is shown as day 0 value. Comparison between no SCM and with SCM: *, P Ͻ 0.05; **, P Ͻ 0.01. days (2T5C, 5C2T (P Ͻ 0.05 as compared to 2T) and 2T3C2T). The 2-day transduction protocol (2T) resulted in a loss of total CFC number (61% as compared to day 0). All four transduction protocols showed a lower total CAFC week 2 and 4 recovery as compared to day 0 (week 2: 35 to 70%; week 4: 41 to 69%). The 5C2T protocol had a very low CAFC week 6 recovery (9%), while in the other three protocols the CAFC week 6 recovery ranged from 21 to 38%.
Stroma-conditioned pre-culture improves recovery of HSC in an ex vivo gene transfer protocol Because of the low CAFC recovery in the transduction protocols containing 3/S/6/␣T, the effect of FBMD-1 or L88/5 SCM was studied. For this purpose we used the 5C2T protocol in
Figure 7
The effect of transduction protocol or stroma-conditioned media (SCM) on retroviral neo gene transfer in and recovery of longterm culture colony forming cell (LTC-CFC) production. (a) The percentage G418-resistant (0.5 mg/ml, active substance) and (b) the percentage recovery of (as compared to input values at day 0: dashed line) non-adherent LTC-CFC week 2 and 4 and combined nonadherent and stroma-adherent LTC-CFC week 6 is shown using the 2T or 5C2T transduction protocols (see Figure 4 ) in serum-free medium containing IL-3, SCF, IL-6 and ␣TGF␤1 with or without FBMD-1 or L88/5 SCM. Percentage G418-resistant LTC-CFC of untreated cells is shown as day 0 value. Comparison between 5C2T (no SCM) and the other three protocols: *, P Ͻ 0.05. which SCM was exclusively added during the 5-day preculture. This protocol resulted in a poor CAFC week-type recovery without the addition of SCM (week 2: 35%; week 4: 41%; week 6: 9%) (Figure 5b ). Figure 6a shows that the preculture with SCM did not improve the transduction percentage of progenitor cells (CFC: 17.3, 18.0 and 11.5%; CAFC week 2: 16.5, 23.0 and 16.8%; No SCM, FBMD-1 SCM and L88/5 SCM, respectively) and that there was only a small improvement of transduction percentage of more primitive HSC (CAFC week 4: 5.9, 12.0 and 9.8%; CAFC week 6: 8.7, 12.5 and 12.3%; No SCM, FBMD-1 SCM and L88/5 SCM, respectively). However, both FBMD-1 and L88/5 SCM pre-culture significantly (P Ͻ 0.05) improved the total recovery of all stem cell subsets during the gene transfer procedure (Figure 6b ). Figure  6c shows that this results in an increased graft size of transduced stem cell subsets as compared to pre-culture without SCM (CFC: 1.9-and 2.1-fold; CAFC week 2: 6.5-and 9.7-fold (P Ͻ 0.05); CAFC week 4: 4.2-and 6.2-fold; CAFC week 6: 5.4-and 7.7-fold, FBMD-1 and L88/5 SCM, respectively).
SCM partly abrogates the loss of CFC producing ability in LTC Next to the recovery of various CAFC subsets, the CFC producing ability of the CD34
+ PBSC before and after retroviral transduction was determined using flask-LTC. The NA-CFC output was determined on week 2 and 4 and at week 6 the combined NA and stroma-adherent CFC output was assessed. In addition, the percentage of G418-resistant LTC-CFC was determined. The transduction rate as measured using the CAFC subsets as an endpoint (Figures 5a and 6a ) reflected that as assessed by the LTC-CFC subsets (Figure 7a ). The total LTC-CFC recovery was lower as compared to the input values (day 0) at all weeks (Figure 7b ) and also lower than the CAFC recovery (Figures 5b and 6b) . The recovery of LTC-CFC was better in the 2-day transduction protocol (2T) (week 2: 39%; week 4: 19%; week 6: 45%) as compared to the protocol with 5-day pre-culture (5C2T) (week 2: 20%; week 4: 8%; week 6: 5%) (P Ͻ 0.05) suggesting that a progressive loss of LTC-CFC ability occurred with increasing culture time of the transduction procedure. The addition of FBMD-1 and L88/5 SCM in the 5-day pre-culture completely neutralized the LTC-CFC loss as compared to the 2-day transduction protocol at week 2 (57 and 72% as compared to day 0, respectively) and week 4 (28 and 30% as compared to day 0, respectively) and only partially at week 6 (14 and 15% as compared to day 0, respectively).
In order to assess the effect of the transduction protocol on the individual CAFC quality, we calculated the mean number of LTC-CFC produced at week 6 per CAFC week 6. Untreated CD34 + PBSC (day 0) formed 5.2 LTC-CFC per CAFC at week 6 ( Table 2) . After 2 days of transduction (2T) or 5 days of liquid culture followed by 2 days of transduction (5C2T) with or without the addition of SCM there was a three-fold lower individual stem cell quality (range: 1.4 to 1.7 LTC-CFC per CAFC week 6). These observations show that the presently discussed transduction protocol (5C2T) effectively introduces the neo gene into primitive HSC, however, at the same time causes their numerical and qualitative loss.
Discussion
In this study, we optimized conditions for retroviral gene transfer into mobilized CD34 + PBSC from cancer patients. As shown before with HSC from normal bone marrow and cord blood 18-21 also mobilized PBSC were more efficiently transduced on carboxy-terminal fibronectin fragment coated dishes. In accordance with Hanenberg et al 21 this can be explained by colocalization of cells and virus particles, because our study showed that CD34 + PBSC adhere very efficiently to CH-296 and Hanenberg et al reported that retroviruses adhere to the heparin-binding domain of CH-296. In addition, we did not observe an effect of CH-296 adherence on the recovery of CFC after 2-and 7-day cultures. Table 2 Mean number of flask long-term culture colony forming cells per cobblestone area forming cell at week 6 before and after retroviral gene transfer Protocol (see Figure 4) LTC-CFC per CAFC week 6 (±1 s.e.m.; n = 3)
CFC, colony forming cell; CAFC, cobblestone area forming cell; LTC, long-term culture; SCM, stroma-conditioned medium.
In a second set of experiments we showed that 5-day preculture specifically improved retroviral gene transfer in primitive PBSC (CAFC week 6) as compared to a 2-day transduction protocol. Apparently, the quiescent primitive stem cells in mobilized peripheral blood needed a prolonged cytokine stimulation before cell cycling and subsequent retroviral integration occurred. This was also suggested by reports on the refractiveness of primitive CD34 + CD38-negative HSC in mobilized peripheral blood to cell cycle activation during a 2-to 3-day cytokine stimulation. 12, 13 In our study, the transduction efficiency of progenitor cells (CFC and CAFC week 2) were comparable in all four transduction protocols, indicating that transduction efficiencies of progenitor cells have no predictive value for that in more primitive HSC. The 7-day culture and transduction protocols (2T5C, 5C2T and 2T3C2T) in serumfree medium containing 3/S/6/␣T resulted in an expansion of CFC, but a loss of all CAFC subsets. The repeated manipulations during the transduction and culture procedures may explain the overall lower recovery of CFC and CAFC as compared to previous PBSC expansion studies of our group. 22, 23 However, the addition of FBMD-1 or L88/5 SCM to the preculture resulted in significantly improved recovery of CFC and all CAFC week-types as was also reported earlier by our group using 7-day expansion cultures of CD34 + PBSC. 22, 23 Although in the present study SCM hardly improved the percentage of G418-resistant HSC, the increase in total recovery of stem cells resulted into an 1.9-to 9.7-fold larger number of transduced stem cell subsets in the graft as compared to cultures without SCM.
Previous studies of our group have shown the importance of stem cell quality assessment. In a selected group of autologous transplantation patients that did not show significant hematopoietic repopulation within 6 months post-transplant, the original grafts contained low CAFC week 6 numbers, while their ability to generate CFC in LTC was even lower. 29 In addition, we have reported that few CAFC week 6 are mobilized in patients that have received intense cytotoxic chemotherapy, and that the quality of those stem cells is very low. 25 In the present study, we observed a total LTC-CFC producing ability that ranged from 5 to 45% of input in four different transduction protocols (2T, 5C2T, 5C2T+FBMD-1 SCM, 5C2T+L88/5 SCM). When these LTC-CFC numbers were corrected for the number of CAFC week 6, it appeared that only 1.4 to 1.7 LTC-CFC was generated per CAFC week 6 in all four transduction protocols as compared to 5.2 LTC-CFC/CAFC in the original graft. From these data we may conclude that irrespective of their numerical recovery, the CAFC week 6 always generated the same mean number of LTC-CFC per CAFC suggesting that all transduction protocols lead to identical losses of individual stem cell quality. Our group has made the same observation after expansion cultures of CD34 + PBSC, 23 indicating that this individual proliferative potential of HSC is always affected during ex vivo manipulation of PBSC under the conditions employed and possibly reflects stem cell aging. [30] [31] [32] This dramatic loss of individual stem cell quality after ex vivo culture of HSC could explain the disappointing results of the clinical gene transfer studies. 2, [6] [7] [8] [9] In our view, CAFC week 6 after ex vivo manipulation do not only produce less LTC-CFC in vitro but may also have reduced in vivo repopulating capacity. Therefore, future clinical gene therapy studies should not only assess the number of genetically transduced stem cells but also their individual repopulating quality.
Finally, a discrepancy has been observed between the high transduction percentage of primitive stem cells measured in in vitro stem cell assays and the low percentages measured in in vivo NOD/SCID mouse models. 33 The authors concluded that these in vivo models assay a more primitive HSC which is resistant to retroviral gene transfer. However, we feel that additional or alternative explanations may be valid. It is known that not all transplanted stem cells will be able to reach the hematopoietic organs and contribute to the hematopoiesis of a recipient. Seeding studies in the murine system have shown that only about 20% of all infused stem cells effectively homes to the total bone marrow and 10% to the spleen, and subsequently initiate hematopoietic regeneration. [34] [35] [36] We have recently found that seeding of human stem cells in NOD/SCID bone marrow is even lower, ie 1 to 5% (PB Van Hennik et al manuscript in preparation). Furthermore, seeding efficiency is affected by the proliferative activity of stem cells. Monette and DeMello 37 showed that cycling spleen colony forming cells show a 50% reduction of their homing efficiency, while more recenty we showed that even a 3-h ex vivo incubation of bone marrow cells resulted in a similar 50% loss of seeding and consequently a 50% reduction of repopulating ability in a mouse model. 36 Stem cells with a stable retroviral vector integration have gone through a proliferative cycle during or shortly after the transfection protocol and consequently may have a seeding disadvantage in vivo as compared to the untransduced cells. Therefore, the very low seeding of human stem cells in NOD/SCID bone marrow together with the reduced seeding capacity of cycling stem cells may easily lead to an inability to detect outgrowth of transduced human stem cells in NOD/SCID mice.
